Levetiracetam (Keppra) was evaluated in a subset of patients aged ≥65 years (n = 78) enrolled in a large (n = 1030) open-label, phase IV trial (the KEEPER trial). A 4-week dose adjustment was followed by a 12-week evaluation period. An overall median reduction in partial seizures of 80.1% (n = 65) was observed. Overall, 76.9% of patients were ≥50% responders, 56.9% were ≥75% responders, and 40.0% were 100% responders. Levetiracetam was well tolerated, with 42.3% of patients reporting one or more adverse events. A total of 15 patients (19.2%) experienced an adverse event that led to discontinuation. Somnolence (n = 13, 16.7%) and dizziness (n = 7, 9.0%) were the most commonly reported adverse events. Despite the limitations of the open-label study design, these data provide information regarding the use of levetiracetam as add-on therapy for the treatment of partial-onset seizures in patients ≥65 years of age, including those requiring concomitant medications.
Bibliographical noteFunding Information:
This study was funded by UCB Pharma, Inc.
Copyright 2017 Elsevier B.V., All rights reserved.